Baptist Cancer Center

The trials here

What the 35 trials at this site are about, from their registry records.

Conditions

• Lung cancer20 trials
• Multiple myeloma5 trials
• Colorectal cancer4 trials
• Gastric and oesophageal cancer4 trials
• Pancreatic cancer4 trials
• Childhood cancers2 trials
• Endometrial cancer2 trials
• Head and neck cancer2 trials
• Myeloproliferative neoplasms2 trials
• Acute myeloid leukaemia1 trial
• Bladder cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• and 9 more

Phase

• Phase 315 trials
• Phase 28 trials
• Phase 1/24 trials
• Phase 13 trials
• Phase 2/31 trial

Status

• Completed13 trials
• Active, not recruiting10 trials
• Recruiting8 trials
• Terminated3 trials
• Withdrawn1 trial

Lead sponsor

• Janssen Research & Development, LLC5 trials
• Amgen4 trials
• Daiichi Sankyo2 trials
• EMD Serono Research & Development Institute, Inc.2 trials
• Incyte Corporation2 trials
• and 18 more

Running trials

• Recruiting

  Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

  NCT07531095· Phase 1· Amgen· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

  NCT07037758· Phase 1· Amgen· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Amgen· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

  NCT06710132· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  NCT06413498· Phase 3· Kite, A Gilead Company· Source

• Active, not recruiting

  A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

  NCT06246110· Phase 2· Eikon Therapeutics· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Amgen· Source

• Active, not recruiting

  A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

  NCT05455320· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  GEMINI-NSCLC: NSCLC Biomarker Study

  NCT05236114· Tempus AI· Source

  Contact: Angela Gates

• Active, not recruiting

  A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

  NCT04988295· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05083169· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  NCT04614103· Phase 2· Iovance Biotherapeutics, Inc.· Source

  Contact: Iovance Biotherapeutics Study Team lungcelltherapy.com

• Active, not recruiting

  CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

  NCT04062708· Phase 2· Alliance Foundation Trials, LLC.· Source

• Active, not recruiting

  A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

  NCT01594723· Phase 2· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer6 recruiting
• Gastric and oesophageal cancer1 recruiting

Closed trials

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· BioNTech SE· Source

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

  NCT05169437· Phase 2· Tempus AI· Source

• Completed

  Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

  NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source

• Completed

  Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

  NCT04968548· Nucleix Ltd.· Source

• Completed

  To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

  NCT04894591· Jazz Pharmaceuticals· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Incyte Corporation· Source

• Completed

  DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

  NCT04825834· Delfi Diagnostics Inc.· Source

• Recruiting

  A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  NCT04657068· Phase 1/2· Artios Pharma Ltd· Source

  Contact: Sarah Cannon Development Innovations

• Completed

  Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

  NCT04155710· Phase 1· Iovance Biotherapeutics, Inc.· Source

• Completed

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

  NCT03901963· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Terminated

  Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

  NCT03520686· Phase 3· ImmunityBio, Inc.· Source

• Completed

  Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

  NCT02649790· Phase 1/2· Karyopharm Therapeutics Inc· Source

• Completed

  A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

  NCT02428712· Phase 1/2· Fore Biotherapeutics· Source

• Completed

  Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

  NCT01996865· Phase 3· Celgene· Source